# In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

> **NCT02489266** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** AKTi-treated TIL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT02489266
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06-24
- **Primary completion:** 2016-06-29
- **Final completion:** 2016-06-29
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489266, "In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02489266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*